Why is big pharma paying billions to take over small companies? Arash Massoudi, the FT's corporate finance and deals editor, explains that as patents expire and the pressure to cut R&D costs rises, large pharmaceutical companies are being forced to make risky bets in search of the next blockbuster drug.

More videos